OMGA Omega Therapeutics
- 2.420
- -0.135-5.28%
- 2.450
- +0.030+1.24%
Omega Therapeutics News
Omega Therapeutics | 8-K: Current report
Omega Therapeutics | 10-K: Annual report
Omega Therapeutics | 8-K: Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
Omega Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(10.678%),Abigail P. Johnson(10.678%)
Omega Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer McCauley Thomas
Omega Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Karande Mahesh
Omega Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Director SCHADE CHRISTIAN S
Omega Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SCHADE CHRISTIAN S
Omega Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Reed Joshua
Omega Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Moore Yan
Omega Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Zeng Ling
Omega Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-HarbourVest Partners L.P.(6.4%),HarbourVest Partners, LLC(6.4%), etc.
Omega Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(9.587%),Abigail P. Johnson(9.587%)
Omega Therapeutics | 8-K: Current report
Omega Therapeutics | 8-K: Current report
Omega Therapeutics: Q3 2023 Earnings Report
Omega Therapeutics | 8-K: Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Omega Therapeutics | 8-K: Current report
Omega Therapeutics | 8-K: Current report
Omega Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Werner Michelle C
Analysis
Price Target
No Data
